Related Experiment Video
Updated: Jun 24, 2025

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment
Published on: June 9, 2023
Curbing Breast Cancer by Altering V-ATPase Action on F-Actin, Heterochromatin, ETV7 and mTORC2 Signaling
1Department of Mechanical Engineering, Texas Tech University, 2703 7th Street, Lubbock, 79409, Texas, USA.
Background/Aims:
Motivated by the vacuolar proton pump's importance in cancer, we investigate the effects of proton pump inhibition on breast cancer cell migration and proliferation, F-actin polymerization, lamin A/C, heterochromatin, and ETV7 expressions, nuclear size and shape, and AKT/mTOR signaling.
Methods:
Lowly metastatic MCF7 and highly metastatic MDA-MB-231 breast cancer cells were treated with 120 nM of proton pump inhibitor Bafilomycin A1 for 24 hours. Cell migration was studied with wound- scratch assays, ATP levels with a chemiluminescent assay; cell proliferation was quantified by a cell area expansion assay. Nuclear size and shape were determined using DAPI nuclear stain and fluorescence microscopy. The levels of F-actin, lamin A/C, heterochromatin, and ETV7 were quantified using both immunocytochemistry and western blots; p-mTORC1, p-mTORC2, mTOR, p-AKT, and AKT were measured by western blots.
Results:
We reveal that proton pump inhibition reduces F-actin polymerization, cell migration, proliferation, and increases heterochromatin in both lowly and highly metastatic cells. Surprisingly, Bafilomycin decreases lamin A/C in both cell lines. Inhibition has different effects on ETV7 expression in lowly and highly metastatic cells, as well as nuclear area, perimeter, and circularity. Bafilomycin also significantly decreases p-mTORC1, p-MTORC2, and MTOR expression in both cell lines, whereas it significantly decreases p-AKT in lowly metastatic cells and surprisingly significantly increases p-AKT in highly metastatic cells. Our proton pump inhibition protocol reduces V-ATPase levels (~25%) within three hours. V-ATPase levels vary in time for both control and inhibited cells, and inhibition reduces cellular ATP.
Conclusion:
Proton pumps promote F-actin polymerization and decrease heterochromatin, facilitating invasion. These pumps also upregulate both mTORC1 and mTORC2, thus highlighting the relevance of vacuolar proton pumps as metastatic cancer targets.
Insights
Proton pump inhibition hinders breast cancer cell migration and proliferation by reducing F-actin polymerization and impacting AKT/mTOR signaling. These findings highlight vacuolar proton pumps as potential therapeutic targets for metastatic cancer.
Area of Science:
- Cell Biology
- Cancer Research
- Molecular Oncology
Background:
- Vacuolar proton pumps play a critical role in cancer progression.
- Investigating proton pump inhibition offers potential therapeutic strategies for breast cancer.
Purpose of the Study:
- To examine the effects of proton pump inhibition on breast cancer cell migration and proliferation.
- To analyze the impact on F-actin polymerization, lamin A/C, heterochromatin, ETV7 expression, nuclear characteristics, and AKT/mTOR signaling.
Main Methods:
- Treatment of MCF7 and MDA-MB-231 breast cancer cells with Bafilomycin A1 (proton pump inhibitor).
- Assessment of cell migration (wound-scratch assay), proliferation (cell area expansion), and ATP levels.
- Quantification of F-actin, lamin A/C, heterochromatin, ETV7, and AKT/mTOR signaling components via immunocytochemistry and western blots.
Main Results:
- Proton pump inhibition reduced F-actin polymerization, cell migration, and proliferation in both cell lines.
- Inhibition increased heterochromatin and decreased lamin A/C, p-mTORC1, p-mTORC2, and mTOR levels.
- Differential effects on ETV7 expression and p-AKT levels were observed between lowly and highly metastatic cells.
Conclusions:
- Vacuolar proton pumps promote F-actin polymerization and invasion by decreasing heterochromatin.
- These pumps upregulate mTORC1 and mTORC2 signaling pathways.
- Vacuolar proton pumps represent a promising therapeutic target for inhibiting cancer metastasis.
Related Concept Videos
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
PI3K/mTOR/AKT Signaling Pathway
Inhibition of Cdk Activity
Abnormal Proliferation
Mitogens and the Cell Cycle
Drugs that Stabilize Microtubules

